Strategic Action At Visteon Is Unlikely, Morgan Stanley Says In Double Downgrade
Shares of auto supplier Visteon Corp (NASDAQ: VC) were hit with a double downgrade from Morgan Stanley Thursday. The stock was down more than 4 percent at the close Friday.
The Analyst
Morgan Stanley downgraded Visteon from Overweight to Underweight and lowered the price target from $123 to $110.
The Thesis
Morgan Stanley's pessimistic expectations for Visteon are due to a less constructive view on the value of instrument and infotainment centers in vehicle architectures, according to the firm's report.
Strategic action is unlikely in the near-term, given Visteon's consistent pattern of insider selling and low insider ownership.
Morgan Stanley is not projecting the same back-end-loaded growth that Visteon has implied for 2021.
Like Harman, which was acquired by SAMSUNG ELECTRONIC (OTC: SSNNF) in March 2017, Visteon could be an acquisition candidate for a buyer looking to access strong relationships with auto manufacturers, according to Morgan Stanley.
The sell-side firm's reduced $110 price target is based on 8.5 times 2019 EV/EBITDA, down from an earlier multiple of 9.5 times.
Visteon does have upside risks if the company secures strong business wins, if the auto supplier gives investors confidence in the achievability of its 2021 guidance or if the company is acquired, according to Morgan Stanley.
The Price Action
Visteon shares are up over 19 percent over the past year.
The stock ended Friday's session down 4.13 percent at $108.76 after losing more than 6 percent the prior day.
Related Links:
Which Is A Better Investment: Automakers, Auto Suppliers Or Car Parts/Service Providers?
Delphi's Spinoff Upside Already Priced In?
Photo courtesy of Visteon.
Latest Ratings for VC
Mar 2018 | Morgan Stanley | Downgrades | Overweight | Underweight |
Feb 2018 | Gabelli & Co. | Upgrades | Hold | Buy |
Feb 2018 | BMO Capital | Maintains | Outperform | Outperform |
View More Analyst Ratings for VC
View the Latest Analyst Ratings
See more from Benzinga
Longbow Sees 40% Upside In Eagle Materials, With Positive Catalysts Ahead
Goldman Sachs: Madrigal Pharma Has Blockbuster Potential In Liver, Cholesterol Treatments
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
